54 related articles for article (PubMed ID: 21384731)
1. Metabolic risk in selected second-generation antipsychotics.
Kerna V; Nosalova G; Ondrejka I
Bratisl Lek Listy; 2010; 111(12):640-3. PubMed ID: 21384731
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications.
Straker D; Correll CU; Kramer-Ginsberg E; Abdulhamid N; Koshy F; Rubens E; Saint-Vil R; Kane JM; Manu P
Am J Psychiatry; 2005 Jun; 162(6):1217-21. PubMed ID: 15930076
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics - a retrospective medical records review.
Wysokiński A; Kowman M; Kłoszewska I
Psychiatr Danub; 2012 Sep; 24(3):314-22. PubMed ID: 23013638
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.
Bou Khalil R
Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up.
Medved V; Kuzman MR; Jovanovic N; Grubisin J; Kuzman T
J Psychopharmacol; 2009 Nov; 23(8):915-22. PubMed ID: 18635691
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Said MA; Hatim A; Habil MH; Zafidah W; Haslina MY; Badiah Y; Ramli MA; Ananjit S; Sapini Y; Shah M; Mahmud B; Bulgiba A; Hairi NN
Prev Med; 2013; 57 Suppl():S50-3. PubMed ID: 23337566
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study.
Kagal UA; Torgal SS; Patil NM; Malleshappa A
J Pharm Pract; 2012 Jun; 25(3):368-73. PubMed ID: 22551560
[TBL] [Abstract][Full Text] [Related]
9. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.
Bobes J; Arango C; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
Schizophr Res; 2007 Feb; 90(1-3):162-73. PubMed ID: 17123783
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics.
Krane-Gartiser K; Breum L; Glümrr C; Linneberg A; Madsen M; Køster A; Jepsen PW; Fink-Jensen A
Nord J Psychiatry; 2011 Oct; 65(5):345-52. PubMed ID: 21428861
[TBL] [Abstract][Full Text] [Related]
12. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
13. A clinical study of the association of antipsychotics with hyperlipidemia.
de Leon J; Susce MT; Johnson M; Hardin M; Pointer L; Ruaño G; Windemuth A; Diaz FJ
Schizophr Res; 2007 May; 92(1-3):95-102. PubMed ID: 17346932
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of metabolic syndrome among Filipino adults aged 20 years and over.
Tanchoco CC; Cruz AJ; Duante CA; Litonjua AD
Asia Pac J Clin Nutr; 2003; 12(3):271-6. PubMed ID: 14505989
[TBL] [Abstract][Full Text] [Related]
15. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.
Patel JK; Buckley PF; Woolson S; Hamer RM; McEvoy JP; Perkins DO; Lieberman JA;
Schizophr Res; 2009 Jun; 111(1-3):9-16. PubMed ID: 19398192
[TBL] [Abstract][Full Text] [Related]
16. Waist-to-Height Ratio and Triglycerides/High-Density Lipoprotein Cholesterol Were the Optimal Predictors of Metabolic Syndrome in Uighur Men and Women in Xinjiang, China.
Chen BD; Yang YN; Ma YT; Pan S; He CH; Liu F; Ma X; Fu ZY; Li XM; Xie X; Zheng YY
Metab Syndr Relat Disord; 2015 Jun; 13(5):214-20. PubMed ID: 25781351
[TBL] [Abstract][Full Text] [Related]
17. Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre.
Tarricone I; Casoria M; Gozzi BF; Grieco D; Menchetti M; Serretti A; Ujkaj M; Pastorelli F; Berardi D
BMC Psychiatry; 2006 Mar; 6():11. PubMed ID: 16542430
[TBL] [Abstract][Full Text] [Related]
18. Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability.
de Kuijper G; Mulder H; Evenhuis H; Visser F; Hoekstra PJ
J Clin Psychopharmacol; 2013 Aug; 33(4):520-4. PubMed ID: 23775048
[TBL] [Abstract][Full Text] [Related]
19. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
20. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross C; Blasey CM; Roe RL; Belanoff JK
Obesity (Silver Spring); 2010 Dec; 18(12):2295-300. PubMed ID: 20339369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
